ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

190
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
bullishTencent
18 Aug 2024 20:43

Hang Seng Index Sep24 Rebal - No Name Changes, Some Capping, 1% One-Way Flow - Total 0️⃣🍔

The HSI committee promised changes to rebalance towards better sector representation and a move to 100 names. That was a couple years ago. Progress...

Logo
371 Views
Share
18 Aug 2024 20:43

HSCEI Sep24 Rebal - Two ADDs, Two DELETEs, Two Surprises, Middling Flows

HSCEI sees two ADDs and two DELETEs, as expected, but one of the ADDs was unexpected, and the main expected ADD was n-o-t added. This will surprise...

Logo
358 Views
Share
18 Aug 2024 10:05

Hong Kong Connect Flows (Aug 16th): Tencent, China Mobile

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent (700 HK) , China Mobile (941 HK) .

Logo
243 Views
Share
16 Aug 2024 01:32

China Traditional Chinese Medicine (570 HK): Relief as Update Favours the Bulls

The monthly update will relieve the bulls, but there remain potential stumbling blocks. Nevertheless, the risk vs. reward remains attractive.

Logo
470 Views
Share
15 Aug 2024 16:38

Technically Speaking, Breakouts and Breakdowns: HONG KONG (AUGUST 15)

Successful returns in Hong Kong has meant getting the industry right! Lygend benefits from moratorium on new nickel mine permits. Sino Bio RX...

Logo
214 Views
Share
x